Effect of Cryotherpy on Hypertrophic Scar
Study Details
Study Description
Brief Summary
Purpose of the study:
The purpose of the study is to evaluate the therapeutic effect of cryotherpy in treating hypertrophic scar.
It will be hypothesized that:
Cryotherapy may not have an effect on hypertrophic scar.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2/Phase 3 |
Detailed Description
The potential of cryotherapy application in vitro data indicated that using freezing treatment on VFFs + TGF-β1 (myofibroblast) modulated ECM turnover toward antifibrosis and normalization, attenuated myofibroblast differentiation, reduced cell migration, and weakened the contractile activity. On both VFFs ± TGF-β1, freezing treatment raised LP regeneration (HAS1, decorin).
The findings indicate that cryotherapy may play a protective role in scar formation and contribute to lamina regeneration.
Furthermore the need of this study was developed from the lack in the quantitative knowledge and information in the published studies about the effect of cryotherapy on hypertrophic scar.
This study will be designed to provide a guideline about the effect of effect of cryotherapy on hypertrophic scar height, thickness and discoloration, and to assist in planning an ideal treatment regimen for reducing hypertrophic scar.
Delimitations:
This study will be delimited in the following aspects:
- Subjects:
Sixty patients suffering from hypertrophic scar will be randomly divided into two equal groups each one has 30 patients.
- Equipment and tools:
2.1. Measurement equipment: Vancouver scar scale. MAPS (Matching Assessment of Scars and Photographs). 2.2. Therapeutic equipment: Gymna Cryoflow ICE-CT. Temperature resistant polymide tape (48 wide).
Hypothesis:
It will be hypothesized that:
Cryotherapy may not have an effect on hypertrophic scar.
Basic Assumptions:
It will be assumed that:
-
All patients will receive the same kinds of medication and the same nursing care.
-
All subjects are free from any chronic disease.
-
All subjects will continue in the study.
-
All patients will follow the instructions during the treatment
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Group A: (control group) This group includes 30 patients will receive routine medical treatment and routine physical therapy as (Exercising, Positioning and splinting, Pressure Therapy and Massage). |
Other: Exercising, Positioning and splinting, Pressure Therapy and Massage
Exercising, Positioning and splinting, Pressure Therapy and Massage
|
| Experimental: Group B: (Study group) This group includes 30 patients will receive cryotherapy (at least 10 minutes at -14 degree , 2 sessions per week , for 10 weeks ) in addition to routine medical and physical therapy treatment. |
Device: cryotherapy (Gymna Cryoflow ICE-CT)
Cryotherapy (also called cryoablation) method was produced by James Arnot in England in 1945 to reduce the size of cancerous cells based on the theory that cold blood cells destroy the cells. Campbell White of New York City used cryotherapy as the first dermatological indication in early-stage epithelioma patients in 1890. Later in 1907, Whitehouse described the use of this method in diferent diseases such as pigmented nevus and lupus. In addition, he has published a case series of skin cancers in different face regions.
Other Names:
Other: Exercising, Positioning and splinting, Pressure Therapy and Massage
Exercising, Positioning and splinting, Pressure Therapy and Massage
|
Outcome Measures
Primary Outcome Measures
- scar height [3 months]
The potential of cryotherapy application in vitro data indicated that using freezing treatment on scar decrease its height
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age range between 20- 40 years.
-
Both sexes will participate in the study.
-
All patients participated will begin treatment program one month after injury depending on injury characteristics.
-
All patients enrolled to the study will have their informed consent.
Exclusion Criteria:
-
Diabetes mellitus.
-
Individuals with cardiopulmonary conditions.
-
Individuals undergoing radiation therapy or chemotherapy.
-
Hepatic or pancreatic diseases.
-
Sensory impairment
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Faculty of Physical Therapy | Cairo | Egypt |
Sponsors and Collaborators
- Zakria Mowafy
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
- Arno AI, Gauglitz GG, Barret JP, Jeschke MG. Up-to-date approach to manage keloids and hypertrophic scars: a useful guide. Burns. 2014 Nov;40(7):1255-66. doi: 10.1016/j.burns.2014.02.011. Epub 2014 Apr 24. Review.
- Atiyeh BS, Hayek SN, Gunn SW. New technologies for burn wound closure and healing--review of the literature. Burns. 2005 Dec;31(8):944-56. Epub 2005 Nov 4. Review.
- P.t.REC/012/002266